Synexus Polska Sp. z o.o.
- Address
- lock Available on a paid plan
Allergy and Respiratory Research at Synexus Polska Sp. z o.o.
This site is actively involved in respiratory tract diseases and immune system processes, with studies focused on conditions such as asthma, chronic obstructive pulmonary disease, and seasonal allergic rhinitis. The trials are designed to assess new treatment options and better control of symptoms in people with ongoing airway and allergy-related disease.
- Testing new approaches for uncontrolled asthma and COPD
- Evaluating relief for seasonal allergic rhinitis and rhinoconjunctivitis
- Studying long-term management of breathing and allergy symptoms
Research at the Wroclaw site includes both adult and pediatric allergy studies, reflecting a broad effort to improve daily disease control and quality of life.
Dermatology and Immune-Mediated Skin Diseases
A major part of the research portfolio centers on skin and connective tissue diseases and immune system diseases, especially atopic dermatitis, plaque psoriasis, prurigo nodularis, and vitiligo. These trials are mainly aimed at finding more effective ways to reduce inflammation, itching, and visible skin symptoms.
- Investigating treatments for moderate to severe atopic dermatitis
- Studying therapies for psoriasis, prurigo nodularis, and vitiligo
- Assessing long-term safety and symptom control in chronic skin disease
The site contributes to research that helps clarify how new therapies may improve comfort, appearance, and day-to-day functioning for people with persistent inflammatory skin conditions.
Gastroenterology and Liver Disease Studies
Clinical trial activity also covers digestive system diseases and related physiological phenomena, with work in Crohn’s disease, eosinophilic esophagitis, and liver conditions such as NASH and MASH. These studies are intended to evaluate whether new therapies can improve disease control, support tissue healing, and slow progression of chronic gastrointestinal and liver disorders.
- Testing treatments for Crohn’s disease and eosinophilic esophagitis
- Evaluating therapies for NASH and MASH with fibrosis
- Measuring long-term benefit in chronic digestive and liver disease
This area shows a strong focus on conditions that can affect nutrition, comfort, and long-term organ health.
Cardiometabolic and Kidney Research
The site runs multiple trials in cardiovascular diseases, nutritional and metabolic diseases, and kidney-related conditions. Main diseases under study include hypertension, hyperlipidemia, obesity, type 2 diabetes mellitus, and chronic kidney disease, with research aimed at reducing future heart and kidney complications.
- Evaluating therapies for high cardiovascular risk and established heart disease
- Studying treatment options for CKD, hypertension, and metabolic imbalance
- Assessing approaches to lower LDL cholesterol and improve cardiometabolic health
These trials reflect a broad effort to improve prevention and long-term outcomes in people at risk of serious vascular and metabolic disease.
Autoimmune, Rheumatology, and Pain Research
Another important research stream includes immune system diseases, musculoskeletal diseases, and musculoskeletal and neural physiological phenomena. Studies are being conducted in psoriatic arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, osteoporosis, and chronic nerve pain, with the goal of improving symptom control and long-term disease management.
- Testing new therapies for psoriatic arthritis and lupus
- Comparing treatment options for postmenopausal osteoporosis
- Studying relief for chronic neuropathic pain
At Synexus Polska Sp. z o.o., these studies support research into conditions that can affect mobility, daily comfort, and long-term quality of life.
Infectious Disease and Vaccine Research
The portfolio includes work in bacterial infections and mycoses and virus diseases, with studies related to respiratory syncytial virus, recurrent herpes labialis, and prevention of invasive extraintestinal pathogenic Escherichia coli disease. These trials aim to improve prevention, strengthen immune protection, and evaluate whether new or combined vaccine strategies can provide better protection.
- Assessing vaccine responses for RSV and influenza
- Studying prevention of ExPEC disease
- Evaluating treatment for recurrent herpes labialis
This area highlights the site’s role in both treatment and prevention research for common and potentially serious infectious diseases.
Neurology, Cognitive Health, and Post-Viral Conditions
The site also supports research in nervous system diseases and related cognitive outcomes, including cognitive impairment associated with post-COVID-19 syndrome and chronic pain syndromes affecting the nervous system. These studies are designed to see whether new therapies can improve thinking, memory, and symptom burden after infection or nerve injury.
- Evaluating treatments for post-COVID cognitive impairment
- Studying therapies for chronic peripheral neuropathic pain
- Exploring ways to improve everyday cognitive function and comfort
The research adds an important dimension to the site’s broader clinical program by addressing conditions that can be difficult to diagnose and manage.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Akero Therapeutics Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Synexus Polska Sp. z o.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | Bristol Myers Squibb International Corporation | Phase II | Not Recruiting | May 2019 | Mar 2025 |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215) | 1 | Unknown | 2023-11-06 | 2023-11-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
